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1. Introduction 
Cervical cancer is one of the most common cancers among women worldwide, currently 
ranked as the third cancer causing death for females (Ferlay et al., 2010). Since the screening 
programs have been implemented the incidence and mortality associated with cervical 
cancer have declined (Gustafsson et al., 1997) but in developing countries it still remains a 
cause of death in women.  
Although essential for the transformation of cervical epithelial cells, HPV is not sufficient, a 
number of other cofactors and molecular events being also incriminated (Woodman et al., 
2007). Cervical HPV infection is a sexually transmitted disease which occurs in women short 
time after beginning the sexual life. In young women, the disease is usually transient, its 
prevalence decreasing around 30 years (de Sanjosé et al., 2007). A second peak of infection is 
found in older women and is superposed to the peak of cervical cancer incidence (Anton et 
al., 2011). Near 40 of the more than 140 HPV types identified so far can infect the cervix 
(Bernard et al., 2010). Differences in carcinogenicity of cervix specific HPV types are 
partially related to the expression of the E6 and E7 oncogenes which, among other functions, 
interfere with tumour suppressor proteins p53 and pRb, respectively (Sinal et al., 2005). By 
these interactions viral oncogenes abrogate the mechanisms of cell-cycle control and 
apoptosis.  
As many studies sustain, in the absence of persistent infection the risk of cervical cancer is 
low (Schiffman et al., 2011). Persistent infection with high risk genotypes and the inability of 
the immune system to clear viral infection are the main factors contributing to tumors 
genesis. Thus, according to new concepts (Snijders et al, 2006), both the immune 
mechanisms of the host and the nature of infected cells are decisive for cervix lesions 
development. It takes 12-15 years before a hrHPV persistent infection may lead to cervical 
carcinoma, thus underlying the multistep process of cervical oncogenesis. Aberrant 
functions of tumour-suppressor genes as a result of their interaction with hrHPV viral 
genes, determine the genomic instability. These alterations cumulated with the action of 
various cofactors lead to progressive lesions and finally to cancer. The epithelial cells 
transformation is a 4 steps process, as proven by in vitro analysis: extended life span, 
immortalization, loss of anchorage and tumorigenic growth (Snijders et al, 2006). Each step 
is characterized by accumulation of (epi) genetic cell changes. 
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There is a continuing interest in the molecular mechanism of HPV oncogenic induction 
program, especially for clinicians who need new markers. Together with HPV DNA and 
PAP tests, these new markers may have additional value for risk assessment of cervical 
cancer and may reduce the number of biopsies. A major challenge for gynaecologists is to 
implement more markers in the routine practice, in order to have a better estimation of the 
risk a cervical lesion has to progress to cancer. Taking into account the contribution of 
oncogenic HPVs to malignant phenotype development by several interrelated mechanisms 
we evaluated the molecular markers (used in a variety of techniques) which might 
characterize different stages of HPV-associated epithelial lesions. The next step is to 
determine their suitability as "surrogate markers". In order to point host genes involvement, 
viral cell cycle has to be known. 
2. HPV life cycle 
All the HPV types infecting cervix are non-enveloped small sized viruses and have about 
8000-base pairs in their double-stranded circular DNA. Their genome has overlapped open 
reading frames, coding for eight proteins, divided into an early (genes E1-E7) and a late 
region (genes L1-L2). The early genes are expressed in the infected basal cells while the late 
proteins are synthesized only in well differentiated cells. The early proteins have regulatory 
functions, being involved in HPV genome replication and transcription, cell cycle, cell 
signalling and apoptosis control, immune modulation and structural modification of the 
infected cell (Molijn et al., 2005; Sinal & Woods, 2005).  
The replication cycle of HPV is tightly linked to differentiation of the epithelium it infects. 
For the initial infection to occur microlesions in the stratified epithelium are requested. 
Although some cell surface receptors have been mentioned, as heparin sulphate (Giroglou et 
al., 2001) and alpha-6 integrin, the controversy persists. It has been suggested that for a 
lesion to be maintained, the virus must infect an epithelial stem cell (Egawa, 2003). 
Following infection, in the basal cells of the epithelium, where low levels of viral early 
proteins (E1, E2, E5, E6 and E7) are observed, a low number of viral genome copies are 
maintained as episome. For viral DNA synthesis, beside E1 and E2 proteins that are 
necessary for viral replication, papilomaviruses use the host cell machinery. Viral 
transcription increases in differentiated cells while assembly of new virions occurs only in 
the squamous epithelia undergoing terminal differentiation. E4 is the first protein expressed 
late in infection and it may be accompanied by E5. The late proteins L1 and L2, are 
expressed in the granular layer of the epithelium and the assembled viruses are released 
from the fully differentiated cells. This pattern of gene expression is characteristic to 
productive infection and its pathological effect is specific for CIN 1 and some CIN 2 lesions. 
A deregulated E6 and E7 expression in proliferating cells and the interference of these viral 
oncogenes with tumour supressor genes p53 and pRB respectively, determine the cells to 
overcome senescence barrier and to develop a transformed phenotype (Fehrmann & 
Laimins, 2003). Recent studies have provided data on how different types of stimuli activate 
signalling pathways leading to senescence. It seems that these stimuli are funnelled through 
p53 and pRB (Narita et al., 2003) whose combined levels of activity determine the cells to 
enter senescence or to remain in a competent state for proliferation (Dirac & Bernards, 2003). 
Usually, the up-regulation of viral oncogenes expression is associated with viral genome 
integration into the host cell chromosome and with viral E2 gene disruption. Loss of the E2 
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leads to the uncontrolled expression of viral oncoproteins, which in turn leads to disruption 
of the normal cell cycle regulation and progres of HPV-associated cervical cancer (Hung et 
al., 2010). E6 and E7 oncoproteins are also required for the maintenance of the transformed 
status of infected cells (Longworth & Laimins, 2004). This pattern is characteristic for high 
grade CIN and carcinoma.  
In terms of HPV pathogenesis, depending on the HPV genotyope involved in the infections, 
there are three types of clinical manifestations: (a) productive infection, characterized by 
virions production and a strictly regulated expression of the viral genes at well defined sites. 
CIN 1 represents the histological manifestation of productive infections. (b) latent/inactive 
infection, rarely visible, without clinical signs (asymptomatic), characterized by 
maintenance of the viral genome in basal layers and early viral proteins expression at levels 
below those necessary to produce an effective immune response. Viral persistence may be 
the consequence of infection in case of immune system depletion and may result from 
silencing expression of viral gene through methylation (Kalantari et al., 2004). (c) abortive 
infection, as a precursor to cancer, is associated in particular with hrHPV genotypes which 
induce changes in virus-infected cells causing cancer. HPV-induced cancers often arise in 
sites which are non-optimal for productive infection. Low risk HPV types are only 
occasionally associated with mucosal cancers. 
3. Biomarkers – Indicators of the disease state 
According to Wentzensen and von Knebel Doeberitz (2007), there are several applications 
for the cancer biomarkers including: (1) early detection of cancers (identification of 
individuals prone to develop cancer at a time point that still allows for a successful curative 
intervention); (2) improved reproducibility of the histopathological diagnoses (allowing for 
risk assessment of detected lesions and stratify intermediate lesions); (3) surveillance of 
persons at risk (allowing for non-invasive monitoring or reduce invasive procedures); (4) 
post therapy monitoring (predicting the progression and monitoring recurrences after 
treatment).  
Approximately 80% of CIN1 lesions regress spontaneously (Follen and Richards-Kortum, 
2000) and usually are managed conservatively. On the other hand, CIN2 and CIN3 have a 
considerable risk of progression toward invasive cancer and are therefore usually treated by 
conization or other less invasive procedures. Anyway, despite its rather low rate of 
progression, CIN2 is frequently treated, fact that leads to contradictory discussions (Spitzer 
et al, 2006; Wright et al, 2003). In order to restrict treatment to CIN1/2 groups, there is a 
need for biomarkers that could discriminate between CIN1/2 with high risk of progression 
and those with high chance to regress spontaneously (Ozaki et al., 2011). Additional 
markers are also necessary to overcome diagnostic inaccuracies due to the existence of 
several CIN mimics, such as immature squamous metaplasia (Duggan et al, 2006; Geng et al, 
1999), or to heterogeneous distribution of dysplastic lesions that can result in over- and 
under-diagnosis.  
A hrHPV positive test without associated important cytological changes would always 
require monitoring. The risk of progression toward invasive cancer increases with the 
lesions’ grade (Ostor 1993), thus, biomarkers specifically associated with disease 
progression, allowing for a correct triage must improve the cervical cancer screening 
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programs and the early detection of people at risk. Therefore, in order to be useful, the 
biomarkers must meet the following criteria: (1) they must be differently expressed in 
normal and high-risk tissues; (2) they should be synthesised in a well defined stage of 
carcinogenesis; (3) both the marker and its assay must be acceptable sensitive, specific and 
accurate; (4) they should be easily measured; (5) they should be correlated with a decrease in 
the cancer incidence rate (Follen and Schottenfeld, 2001). The inherent variability in 
interpretation between individuals has led to wide ranges in diagnostic precision between 
practices, but the advent of immunohistochemistry and the more recent discovery of new 
genes and their functions have resulted in the identification of cellular proteins that are 
differently expressed in tumours (Nucci et al., 2003).  
3.1 Cell cycle regulation markers 
The loss of cell-cycle control by HPV oncoproteins directly or indirectly interacting with the 
host genes (Giannoudis et al., 2000) leads to accelerated proliferation mirrored by an 
increased number of cells expressing specific markers. Among cyclins and cyclin dependent 
kinases (CDKs) that governed cell cycle, p53, Rb and CDK inhibitors (p15, p16, p18, p19, 
p21, p27) play a special role by arresting the cell cycle until damaged DNA is completely 
repaired. Therefore, the cell cycle regulators may shed light on the understanding of HPV-
mediated cervical carcinogenesis (Conesa-Zamora et al., 2009).  
The roles played by cyclins and CDKs in distinct phases of the cell cycle, suggest that they 
could be used as markers for cell proliferation in cervical malignancy (Skomedal et al., 1999).  
The ability of HPV oncoproteins to disrupt growth regulatory proteins may have effects 
on the cyclin-dependent kinase inhibitors linked to the G1- and G2- checkpoints. As 
mentioned before, cell cycle deregulation in cervical carcinogenesis is by far linked to p53 
and pRb. The degradation of p53 tumour-suppressor gene by E6 may result in 
accumulation of damaged DNA. By contrast with other cancers where p53 appears to be 
down-regulated by point mutations, in cervical cancer p53 expression seems to be 
increased; the levels of p53 in high-grade SIL (HSIL) and cervical carcinoma is higher than 
in low-grade SIL (LSIL) and normal cervix. There are authors who reported higher p53 
expression in cervical biopsy specimens from patients without HPV infection or who 
where infected with low-risk HPV (Tsuda et al., 2003). Conflicting results on this topic 
have been published: some studies showed a significant correlation of p53 expression 
with CIN 3 or carcinoma compared with normal cervix or LSIL (Bahnassy et al., 2007) 
whereas others showed no significant association. These results suggest that the absence 
of p53 immunostaining might be due to the capacity of some hrHPVs to down-regulate in 
different extent the p53 expression, probably via E6-induced ubiquitination. Over-
expression of p53 does not seem to be related to HPV oncoprotein action, as some authors 
noted higher expression of p53 protein in early lesions. These data support the hypothesis 
of a partially protective role of the wild-type p53 in the early stages of cervical lesions 
(Vassallo et al., 2000) and is correlated with the observation that high levels of p53 
expression are detected mostly in low-grade SILs (LSILs) and lrHPV-associated lesions 
(Kurvinen et al., 1996). Thus, p53 might function as a molecular marker for the risk of the 
progression of HPV-associated SILs. Øvestad et al, (2011) reported that CIN2–3 lesions 
regressed if higher epithelial pRb and p53 levels were present. Therefore, they proposed 
p53 and pRB as biomarkers. One paper noted that in HPV-positive or –negative low CIN 
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or ASCUS, in the majority of cases, p53 was overexpressed in the basal cell layer, thus 
presenting a positive response to viral infection or to the lesion (Cenci et al., 2005). A 
paper reported that the majority of CIN showed absent to focal staining while most of the 
invasive carcinoma showed regional to diffuse staining. A greater expression of p53 in the 
malignant cervical neoplasms than in the pre-malignant cervical lesions was noted, 
suggesting that p53 overexpression is not an early phenomenon in cervical cancer (Tan et 
al., 2007). p53 control the G1 transition to S phase and its abrogation affect the expression 
of p16, p21 and p27 cyclin inhibitors. p21, p27 and p57 CDK inhibitors inhibit the 
cyclin/CDK2, CDK4 complexes and causes G1 arrest. The levels of these proteins are of 
prognostic significance in cervical oncogenesis. p27 might be inactivated early in 
carcinogenesis by E7 hrHPV and may precede tumor invasion (Zur Hausen, 1994).  
p16 is a tumor suppressor protein belonging to the family of INK4 cyclin-dependent-kinase 
inhibitors whose increased expression has been associated with HPV-infected dysplastic 
and neoplastic epithelium of the cervix. p16 expression is the result of negative feedback on 
functional inactivation of pRb by E7 HPV (Zur Hausen 1994). p16 protein normally acts like 
a negative regulator of cellular proliferation, but its inhibitory action is not efficient in the 
case of proliferating hrHPV infected cells (Dray et al., 2005). Most studies confirm p16 
overexpression in all HSIL lesions but also in some normal epithelium of cervix at both 
protein (von Knebel Doeberitz et al., 2002) and messenger levels (Bleotu et al., 2009). On the 
other hand, p16 is not expressed in cervicitis nor is in squamous metaplasic epithelium (in 
the absence of CIN stages) (Hu et al., 2005). Still, other studies proved that p16 high level 
was found in cervical glandular epithelium and also in metaplasic epithelium. Therefore 
immunohistochemical analysis of p16 is considered a powerful tool in the identification of 
HPV-mediated premalignant and malignant lesions of the uterine cervix. Cytoplasm 
predominant localization of p16 seems to be related to the increasing histological grade of 
cervical lesion (Horn et al., 2006). Yıldız et al. found strong and full thickness staining for 
p16 in the cervix epithelium in HSIL lesions and weak and basal/rare staining in LSIL. All 
hrHPV-positive cases were p16-positive, but no statistically significant relationship between 
HPV infection and the intensity and distribution of p16 was found (Yıldız et al., 2007). 
Depending on the positive cells distribution, there have been recognised four patterns of p16 
staining which correlate to the lesion’s grade (Kostopoulou et al., 2011). 
Cyclins such as cyclin D1 are subjected to molecular alterations that characterize cervical 
carcinoma. Cyclin D1 forms a complex with CDK4 or CDK6 to carry out the 
phosphorylation of pRb. The phosphorilation of pRb leads to the release of the 
transcriptional factor E2F which, in turn, induces the expression of proteins required for S 
phase. Since D type cyclins and E7 HPV possess similar binding regions for pRb and pRb 
related pocket proteins, inactivation of pRb either by the cyclin/CDK complexes in G1 or by 
interaction with the E7 hrHPV may result in a decreased expression of cyclin D1. There are 
controversial results on the role of cyclin D1 in cervical carcinogenesis and clinical outcome 
(Goia et al., 2010). Although some studies reported no correlation between the expression of 
D1 cyclin and dysplasia (Goia et al., 2010) some authors associated overexpression of cyclin 
D1 with a poor prognosis in cervical carcinoma (Bae et al., 2001). An increase in cyclin D1 
expression was observed from CIN 3 to invasive carcinoma as a consequence of the inability 
of overexpressed p16 to inactivate CDK4/6, the partner of cyclin D1. The authors suggested 
that the immunohistochemical expression of cyclin D1 might be a marker in cervical cancer 
progression only if restricted beyond to the lower third layer (Conesa-Zamora et al, 2009). 
www.intechopen.com
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
80
Moreover, cytoplasmic staining is more noticeable in the basal and parabasal layers, 
suggesting a recently acquired alteration related to a high-grade dysplasia and the 
progression of the disease (Baldin et al., 1993). A significant increase in the cytoplasmic 
staining associated with an increasing degree of dysplasia was reported by Carreras et al. 
(2007) due to the fact that the number of cells in the S phase increases in severe lesions. This 
finding gives support to the cytoplasmic expression of p16 in lesions of higher grade since 
p16 is the inhibitor partner of cyclin D1 and they often appear together (Zhao M., et al., 
2006). The relationship between cyclin D1 expression and an increasing degree of dysplasia 
was not as remarkable as that seen for p16 but was statistically significant. 
Cyclin B1 complexes solely CDK1 (cdc2) to form the mitosis-promoting factor, which 
regulates the G2–M transition and is the primary regulator of mitosis. p53 was shown to 
prevent the G2–M transition by decreasing cyclin B levels. Some authors reported 
significantly cyclin B1 expression in invasive cervical cancer than in normal cervical tissue 
(Zhao P., et al., 2006).  
Cyclin E is expressed and associated with CDK2 near the G1-S boundary. Cyclin E 
hyperexpression is related to pRB inactivation by E7HPV but can not be correlated with 
hrHPV types. Recent studies have shown that cyclin E antigen correlates with the presence 
of HPV in atypical squamous epithelial cells. The association is stronger in LSIL, thus 
recommending this potential biomarker as a useful tool in distinguishing between 
benign/reactive changes from preneoplastic squamous atypia (Weaver et al., 2000). Much 
more common in cervical lesions versus non-neoplastic epithelium, cyclin E sensitivity may 
hamper its use as a marker (Crum, 2000). Other authors consider cyclin E together with p16 
as the most sensitive tools for LSIL and HSIL detection respectively (Keating et al., 2001). In 
ThinPrep samples, cyclin E and p21 expression seems to correlate better with HSIL (Moore 
et al., 2005). The Cyclin E/CDK2 complex phosphorylates p27, tagging it for degradation, 
thus promoting expression of cyclin A with progression toward the S phase. A close 
association between hrHPV and cyclin A1 was noted (Goia et al, 2010). This could be 
explained by its complex up-regulation by both E7 and E6 oncoproteins, making cyclin A 
active in both S phase and late G2 phase of the cell cycle. Cyclin A1 might be a useful 
marker of cell proliferation most notably orchestrated by the capability of E7 to abrogate the 
inhibitory activity of p21CIP1/WAF1/SDI1 on CDK and proliferating cell nuclear antigen–
dependent DNA replication necessary for the G1-S transition (Erlandsson, F. et al, 2006). 
Studies on cyclin A as prognostic marker are limited.  
Immunohistochemistry investigation of several cell markers (cyclin D1, cyclin E, CDK4, p53, 
mdm-2, p21, p27, p16, Rb and Ki-67) revealed that aberrations involving p27, cyclin E, CDK4 
and p16 are early events in HPV 16 and 18-associated cervical carcinoma, whereas cyclin D1 
and p53 pathway abnormalities are considered late events. Therefore, the authors 
considered that immunohistochemical tests for p16 and cyclin E could be useful in early 
diagnosis of cervical carcinoma (Bahnassy et al., 2007). 
E7 HPV binds to and blocks the function of p21 and p27 in a p53-independent manner 
(Zehbe et al., 1999). Both p21 and p27 are involved in cell cycle arrest through binding to G1 
phase cyclin–CDK complexes. E7 hrHPV modulates the cytoplasmic localization of p27 and 
inhibits p21 function. Some studies showed that p21 immunoreactivity seems to be 
significantly correlated with high grade stage of cervical disease. The protein was reported 
to be significantly increased in CIN3 and in situ carcinoma. On the other hand, p27 was 
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reported to decrease from normal cases to carcinoma (Cheung et al., 2001). On the other 
hand, Huang et al. (2010) reported that p21 expression decreased in HPV 18 positive 
carcinomas. The fact that aberrant expression of p27, cyclin E and p16 are early events in 
carcinogenesis (while p21 occur late in cervical carcinogenesis) might be of interest for early 
diagnostic and for monitoring patients with cervical dysplasia (Bahnassy et al, 2007). No 
established relationship was found between p27 expression and cell proliferation in cervical 
cancer (Kumar & Verma, 2006).  
3.2 Proliferation markers 
Those cells with high proliferative activity that allow the accumulation of transforming 
mutations are more likely to be associated with premalignant and malignant tissues. The 
proliferative aspects distribution in specific layers (basal vs. parabasal vs. superficial) might 
indicate growth-regulatory mechanisms; thus the relation between proliferation and growth 
deregulation is of interest (Heatley, 1998). Proliferation in the normal cervix, in cervical 
intraepithelial neoplasia and in invasive cervical carcinomas can be assessed by a range of 
techniques requiring technologies of varying sophistication and accessibility, considered in 
four broad groups (Heatley, 1998): (l) mitotic counts on routinely processed histological 
sections and cytological smears; (2) in vivo or in vitro incorporation of tritiated thymidine in 
actively proliferating cells, by injection into the cervix and by incubation with fresh tissue, 
respectively; (3) immunohistochemical techniques for Ki-67 labelling index and AgNOR 
counts; (4) flow cytometry.  
In the normal cervix, mitotic activity (quantified in routinely processed histological sections 
and cytological smears or by tritiated thymidine incorporation) is usually confined to the 
basal and parabasal layers, but in CIN the numbers and height of mitotic figures within the 
epithelium increases. The presence of mitotic figures is part of routine diagnosis and 
biomarker value is discussed as a whole.  
Flow cytometry DNA content analysis on minced biopsy specimens (Melsheimer et al. 2004) 
or smear (Tong et al., 2009) allow the association between aneuploidy and dysplasia degree. 
lrHPV types tend to be associated with polyclonal lesions whereas hrHPV types are 
associated with monoclonal lesions (Park et al, 1996). Ploidy appears to be a measurable 
biomarker and a good predictor of the biological behaviour with a better predictive value 
than the histopathologic characteristics (Follen and Schottenfeld, 2001). It is considered that 
in advanced dysplastic lesions, aneuploidy precedes HPV integration, further supporting 
the notion that integration of viral genomes is the consequence and not the cause of 
chromosomal instability and transformation (Melsheimer et al. 2004). Therefore, an 
increased aneuploid DNA value together with the increase in grades of cervical dysplasia 
are specific prognostic markers of malignancy (Kashyap & Das, 1998); flow cytometric 
analysis of DNA ploidy may be a potential means providing a strategic diagnostic tool for 
early detection of cervical cancer (Melsheimer et al. 2004). The combination of DNA ploidy 
(determined by cytometric test) with HPV screening and cytology is an optimal method to 
detect progressive lesions since it has the highest sensitivity and specificity (Singh et al. 
2008).  
Some proliferating molecules were investigated by immunohistochemistry like biomarkers 
in cervical precursor lesions: PCNA, Ki67, ICBP90, etc. 
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Ki-67 is a nonhistone protein expressed in the nucleus during the whole cell cycle, except 
for the early phases of G0 and G1. It constitutes a marker for proliferating cells and was 
associated with severe dysplasia and cervical cancer (Sarian et al., 2006). Ki-67 stains 
positive in the parabasal, basal and intermediate layers of condylomas, in the basal and 
parabasal layers of CIN; in addition, cells positive for Ki-67 staining are identified in 
intermediate and superficial layers of the squamous epithelium. Ki-67 expression 
correlates positively with histologic grade and distinguishes non-diagnostic atypia from 
SIL. The grade and pattern of Ki-67 expression in precursor lesions are still topics of 
debate (Vijayalakshmi et al., 2007). Even Ki-67 is not as specific as p16 for precancerous 
lesions, its immunohistochemical diffuse pattern is associated with a severe lesion. A lot 
of studies were conducted in order to establish the objective, reproducible, and reliable 
use of Ki-67 in the classification of dysplastic changes in cervical epithelium. Expression 
of Ki-67 (MIB-1) in the upper layers/superficial layers of the epithelium corroborated 
with more than 15% of basal cells positive for MIB-1 staining can be used to distinguish 
condyloma from inflammation or squamous metaplasia (Mittal and Palazzo, 1998). Ki-67 
evaluation can be also a valuable adjunct in the distinction of CIN from normal or benign 
cervical squamoepithelial lesions (Kruse et al., 2002; Keating et al., 2001). MIB-1 
expression in the basal and the upper-third layer proved useful in grading SIL with 
equivocal mitotic index (Popiolek et al., 2004). Immature squamous metaplasia can be 
MIB-1 cluster positive, but this false-positive case showed a special staining pattern, 
different from CIN: 1) MIB-1 staining in the nuclei is not diffuse (as in CIN) but clumped; 
2) positive nuclei are somewhat less densely packed than in CIN (Kruse et al., 2002). 
Noteworthy is that the presence of a cluster of at least two MIB-1-positive nuclei (MIB-C) 
in the upper two thirds of the epithelial thickness is a highly sensitive and specific marker 
to discriminate between normal epithelium and low-grade squamous intraepithelial 
lesion (Pirog et al., 2002). Cauterized dysplastic/condylomatous epithelium showed 
significantly greater expression of MIB-1 than cauterized normal epithelium, being a good 
marker (Mittal 1999).  
Recent studies showed that two cell cycle–related proteins, minichromosome maintenance 
protein-2 (MCM2) and topoisomerase II-ǂ (TOP2A) are overexpressed in cervical cancer. 
Minichromosome maintenance protein 2 drives the formation of pre-replicative complexes 
in G1 phase; overexpression of MCM2 provides the link between oncogenic HPV infection 
and the molecular event of cervical dysplasia (Rihet et al, 1996). DNA TOP IIA is a nucleic 
enzyme that plays an important role in DNA replication, transcription, recombination, 
condensation, and segregation through interaction with the double-helix DNA (Ofner et al, 
1994). ProEx C is a cocktail of two monoclonal antibodies that targets the expression of these 
two proteins (MCM2 and TOP II A) and its increased expression is associated with HSIL 
lesions. The ProExC signal is intense, diffuse and comprises the entire thickness of the 
epithelium in HSIL, with a variable pattern of the staining in LSIL, and is usually negative in 
reparative or reactive immature squamous metaplasias (Pinto et al., 2010). ProEx C positive 
expression seems to be more specifically associated with SIL than Ki-67 positive expression 
(Conesa-Zamora et al, 2009). ProExC immunostaining, when compared with p16 
immunostaining, have similar specificity for CIN 2+ and higher specificity for CIN 3+ but 
lower sensitivity for CIN 2+ and CIN 3+ (Guo et al., 2011). Some reports suggested that 
ProExC can be more selective and informative for the progression of low-grade (CIN1) and 
moderate-grade (CIN2) lesions than Ki67 (Beccati et al., 2008). 
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ICBP90 protein is a member of a nuclear proteins family with DNA-binding properties 
involved in DNA replication. ICBP90 detection, used as a proliferation marker (Hopfner R, 
et al, 2000), gives information only concerning the number of cells that entered the cycle 
without any indication on the duration of the cycle. ICBP90 like Ki67 was linked to the 
development of an HSIL. 97.6% of HSILs positively stained for ICBP90; thus confirms it as a 
useful proliferation marker (Lorenzato et al., 2005). If an hrHPV type was present, the 
association of a suspect DNA profile with a positive proliferation marker could predict the 
presence of HSIL in a very accurate way. On the other hand the association of a suspect 
DNA profile with the presence of ICBP90-positive cells and MIB-1 in the upper two thirds of 
the epithelium could help to discriminate between an LSIL and an HSIL with high PPV, 
(Lorenzato et al., 2005).  
3.3 Markers of epithelial organization and differentiation 
The life cycle of human papillomaviruses (HPVs) is tightly linked to the differentiation 
program of the host's stratified epithelia that it infects. Viral infection induces changes in 
squamous differentiation, which is reflected by the pattern of cytokeratin polypeptide 
expression. By studying this pattern in relation with the presence of the virus, it was 
obtained an indication on the influence the virus has in individual cells, on the cellular 
differentiation. For example, E1-E4 contributes to different processes in both the early and 
late stages of the virus life cycle (Nakahara et al., 2005). The viral E1-E4 protein contributes 
to the replication of the viral genome as a nuclear plasmid in basal cells. Expression of the 
HPV-16 E1–E4 protein in human keratinocytes results in the total collapse of the cytokeratin 
matrix, but nuclear lamins and tubulin and actin networks are unaffected (Doorbar et al., 
1991). On the other hand, the presence of the skin-type cytokeratins CK1 and CK10 in 
condylomata accuminata derived from anogenital skin (HPV 6 and HPV 11 positive) was 
decreased, whereas CK13 and to a lesser degree CK4 appeared increased (Mullink et al., 
1991).  
HPV infection may alter the differentiation status of the epidermis leading to a major 
expression of K14 in the basal and suprabasal layers (like in HPV infected normal 
epithelium), up to the more superficial layers (like in epidermodysplasia verruciformis, EV) 
(Barcelos & Sotto, 2009). Comparing the morphologic distribution of cytokeratins 13 and 14 
and involucrin in naturally occurring low-grade SILs and high-grade SILs infected with a 
variety of HPV types, Southern et al., (2001) observed that: (1) the absence of cytokeratin 14 
expression is associated with high-risk HPV infection and occurs more frequently in high-
grade SILs; and (2) dedifferentiation, with loss of cytokeratin 13 or involucrin expression 
occurs only in high-grade lesions. Also, it was noted that in most LSILs infected with 
lrHPVs, cytokeratin 14 expression was present in all epithelial layers, with fewer lesions; the 
expression confined to the basal/parabasal layers with focal loss of expression. By contrast, 
only in few cases (11%) of LSILs infected with hrHPVs, cytokeratin 14 expressions was 
present in all epithelial layers; most of these lesions showed cytokeratin 14 expression 
confined to the basal/parabasal layers (56%), with a number of lesions showing focal loss of 
expression (33%) (Southern et al 2001). Loss/reduction of cytokeratin 14 protein expression 
level is associated with transformation but not immortalization because in HPV16 
immortalized keratinocytes downregulation of cytokeratin 14 occurred only at a 
transcriptional level (the protein level remaining normal) (Bowden et al, 1992). In 
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epidermodysplasia verruciformis CK1/10 showed retarded or negative expression and e-
cadherin is diminished in superficial koilocytotic cells' foci, more superficially in EV. 
Positive staining for K16 and K4 was observed in normal HPV infected epithelium as in EV 
(Barcelos & Sotto, 2009). 
Regauer & Reich (2007) found the following profile for the CK17: when antibodies against 
CK17 were used, the columnar endocervical epithelium showed no staining; basal 
keratinocytes in ectocervical glycogenated squamous epithelium have inconsistently, focally 
and weakly CK17 expression in cytoplasm; the proliferating cells of immature squamous 
metaplasia stain positive for CK17 in the subcolumnar reserve cells and in the proliferating 
basal and suprabasal cells, and negative for columnar cells; the mature metaplastic 
epithelium presents decreased or even lack of CK17 expression; high-grade dysplasia show 
concomitant staining of both CK17 and p16. They sustain a mutually exclusive 
immunohistochemical profile of CK17 and p16 that allows the separation of immature 
metaplasia with or without reactive atypia (characterized by strong, uniform CK17 staining 
of the proliferating cells with concomitant p16 negativity) from CIN III (characterised by 
strong diffuse staining of p16 in all dysplastic proliferating cells). The dual expression of 
CK17 and p16 in atypical squamous lesions with metaplastic features can sustain the 
hypothesis that CIN III alternatively may develop via HPV infection of metaplastic cells.  
Considering all these aspects, we can say that in order to establish the correct diagnostic, all 
potential markers involved in epithelial reorganization and differentiation must be 
synchronic evaluated with other proliferating markers.  
Plasma membrane expression of caveolin-1 (Cav-1), a constituent of lipid rafts and regulator 
of cell signalling, increases by the E5 HPV16 oncoprotein through the C-terminal 10 amino 
acids of E5. Moreover, E5 induces a 23- to 40-fold increase in the lipid raft component, 
ganglioside GM1, on the cell surface and mediates a dramatic increase in caveolin-1/GM1 
association, a potential mechanism for immune evasion by the papillomaviruses 
(Suprynowicz et al., 2008). This phenomenon is very important in productive infection, in 
production of viral progen. But, an inverse relationship between Cav-1 expression and 
transformation has been clearly established. Cav-1 levels are reduced in transformed cells 
and forced reexpression of Cav-1 could abrogate anchorage-independent growth in 
transformed cells (Williams & Lisanti, 2005). In HPV transformed cells, caveolin-1 is 
downregulated and its expression is reduce by E6 HPV (Razani et al, 2000). In a small 
percentage of cervical cancer tumors caveolin-1 silencing occurs via promoter methylation 
(Chan et al., 2003; Dueñas-González et al, 2005). 
E-cadherin is a transmembrane protein with a cytoplasmic domain connected to the actin 
cytoskeleton through association with cytoplasmic proteins, ǂ-, ǃ-, and Ǆ-catenins 
(Piepenhagen & Nelson, 1993; Hinck et al, 1994). E-cadherin is essential for cell-to-cell 
junction and for cellular adhesion, being responsible for cellular interconnection, 
segregation of cell types, differentiation, epithelial polarization, cell stratification, signaling, 
cell motility and proliferation. Loss of E-cadherin function or expression has been implicated 
in cancer progression and metastasis. Down-regulation of E-cadherin was closely associated 
with progressive CIN and cell proliferation (Branca et al., 2006a) in HPV-positive tissue but 
not in the HPV-negative tissue (Samir et al., 2011). E-cadherin downregulation result in an 
increased cellular motility and metastasis.  
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Tissue transglutaminase 2 (TG2), member of calcium dependent enzymes family (Peng et 
al., 1999), is a cytosolic protein that catalyzes the formation of a covalent bond between the 
gamma carboxamide group of peptide bound to glutamine residue and the primary amino 
group of a wide variety of proteins leading to their post-translation modification (Boehm et 
al., 2002). TG2 induce polyamination of retinoblastoma protein, protecting it from caspase-
mediated cleavage (Boehm et al., 2002), but also of HPV E7 disruption (the interaction of 
HPV E7 and pRb is a major step for cervical carcinogenesis) (Jeon et al. 2003). 
TG2 levels in CIN1 are high, reflecting cellular response to inflammation and HPV 
infection and facilitating cell survival by its interaction with proteins involved in cell 
proliferation and cell death. In CIN2 and CIN3, the immunoreactivity for TG2 remains at 
moderately high levels, but typical for these cases, as compared with CIN1, it appears to 
be specifically expressed into nucleus. These nuclear translocations of TG2 in the high-
grade CIN were associated to cell survival or anti-apoptotic phenotype, and therefore aid 
the progression or persistence of the CIN lesion. TG2 is a potentially useful marker for 
low-grade dysplasia or CIN1 lesions because there are clear differences between normal 
and CIN1 epithelium. On the other hand, TG2 represents one potential biomarker due to 
the nuclear/nucleo-cytoplasmic staining of TG2 in high-grade dysplasia (CIN2/3); that 
type of staining is not observed in normal cervical epithelium or generally in CIN1 lesions 
(Gupta et al., 2010).  
3.4 Transcription factors and cell signalling pathway 
Transcription factors are the principal modulators of gene expression and are involved in 
various processes controlling normal and transformed cell behaviour. Viral transcription is 
known to be positively regulated by glucocorticoid hormones via the up-stream regulatory 
region, which may partly explain its contributing effect to the transformation (Gloss et al, 
1987; Mittal et al, 1993). However, in the complex picture of cervical cancer, hormone actions 
represent only one cofactor of HPV transformation. Thus, whatever the mechanism leading 
to carcinogenicity, there is a complex activation of transcription factors.  
Previous studies demonstrated a functional involvement of the AP1 transcription factor in 
HPV-induced cervical carcinogenesis. Transcriptional activation of HPV in a keratinocyte-
specific manner, depend on specific interaction between several nuclear factors and specific 
sites from LCR of certain HPV genotype. AP1 appears to be a common regulator of various 
HPV types expression, which act directly or through additional HPV type-specific that 
cooperate with AP1 to achieve full activation of virus gene expression (Butz & Hoppe-
Seyler, 1993; Mack & Laimins, 1991; Kyo et al., 1995; Chan et al., 1990; Chong et al., 1991). 
Transcriptional regulation of HPV16 is activated also by NF1, TEF- 1, TEF-2 and Oct1 factors 
(Chan et al., 1990; Chong et al., 1991; Ishiji et al., 1992).  
In HPV productive infection, E6/E7 transcripts were found to be expressed in most cellular 
layers with a reduced level of expression in the differentiated cells. E6/E7 expression was 
shown to correlate with AP1 factors distribution, suggesting that AP1 plays a significant role 
in the expression of viral oncogenes in uterine cervix differentiating epithelia. Co-expression 
of two proliferation inductors, AP1 and E6/E7, in undifferentiated cell layers might create a 
positive regulatory loop, contributing to the maintenance of initial HPV infection and 
subsequent activation in basal and suprabasal cellular layers (Kyo et al., 1997). 
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Aiming to obtain information about alterations in the expression of AP1 family members, de 
Wilde et al. (2008) found that, starting from immortal stages, c-Fos, Fra-2 and JunB 
expression became up regulated towards tumorigenicity while Fra-1, c-Jun, Notch1, Net and 
CADM1 became down regulated. They established that if the onset of deregulated 
expression of various AP1 family members became already manifest during the immortal 
state, a shift in AP1 complex composition appeared as a late event associated with 
tumorigenicity (de Wilde et al., 2008).  
Nuclear factor-kappa B (NF-kB) is a ubiquitously expressed transcription factor, which has 
an important role in intracellular regulation of immune response, inflammation, and cell 
cycle regulation (Nair et al., 2003; Niederberger & Geisslinger, 2010; Hayden & Ghosh, 
2011). NF-κB is one of the targets through which HPVs could interfere with the 
transcriptional control in cervical carcinogenesis (Spitkovsky et al., 2002; Fontaine et al., 
2000). The oncogenic HPVs action on NF-kB through several ways: 1) there is a functional 
NF-kB binding site within the HPV16 LCR (long control region), at position 7554–7563, 
acting as an effective repressor of HPV transcription (Fontaine et al., 2000); 2) involvement 
of viral oncogene: hrHPV E7 inhibits NF-kB activation and nuclear translocation and 
prevents its binding to the responsive DNA elements, e.g. the LCR of hrHPV. On the other 
hand, hrHPV E6 inhibits NF-kB (p65)-dependent transcriptional activity within the nucleus, 
thus further contributing to the escape of hrHPV from the transcriptional control of NF-kB 
(Spitkovsky et al., 2002; Nees et al., 2001). Thus, NF-kB is one of the targets through which 
these HPVs could interfere with the transcriptional control in cervical carcinogenesis.  
Using immunohistochemistry it was demonstrated that NF-kB is constitutively activated in 
high-grade CIN (Nair et al., 2003). In term of stain pattern, the intensity of cytoplasmic NF-
kB expression increased along with the increasing grade of CIN, being most frequent in 
invasive carcinomas. There was no detectable nuclear NF-kB expression in the normal cervix 
or CIN1 and CIN2 lesions; an intense nuclear expression appears very rare, even in CIN3 
and cervical cancer and is related to hrHPV (Branca et al., 2006b). Like biomarker, 
increased/normal cytoplasmic NF-kB expression can distinguish CIN with high specificity, 
but low sensitivity. On the other hand, the nuclear expression suffers from lower sensitivity. 
Studies accomplished by Branca et al, (2006b) clearly demonstrated that neither cytoplasmic 
nor nuclear NF-kB staining is a significant predictor of the clearance/persistence of hrHPV 
types after treatment of CIN.  
The ERK/MAPK cascade has been reported to be activated in cervical cancer cell lines both 
by hrHPV and by some low-risk HPV types. In normal squamous epithelium of the cervix 
as well as in metaplastic squamous cells, Branca et al (2004) found weak cytoplasmic ERK1 
expression confined mostly to the parabasal layers. Intranuclear staining is detected in CIN 
lesions that increase in both intensity and extent towards higher grade CIN lesions.  
ERK1 expression showed poor specificity for predicting hrHPV, and do not have a practical 
value as a predictor of hrHPV in cervical cancer and its precursors. Although E5 HPV seems 
to mediate overexpression and activation of the ERK/MAPK signalling cascade, multiple 
other mechanisms that mediate the activation of ERK/MAPK pathways might be involved. 
Despite the fact that ERK1 expression seems to be an early marker of cervical carcinogenesis, 
it is not a specific marker of hrHPV in CIN and cervical cancer, and does not predict disease 
outcome in the latter. 
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3.5 Apoptotic markers 
Apoptosis or programmed cell death is initiated by two types of biological signals: (1) 
extrinsic - the specific ligands activate their receptors (Fas-Fas ligand interaction) and (2) 
intrinsic – mitochondrial pathway used in response to non-specific stimuli (such as 
alteration of DNA, radiation and osmotic stress), leading to release of cytochrome c. Both 
paths lead to the activation of caspase 3.  
In HPV infected cells, inhibition of apoptosis may be a mechanism to promote viral 
persistence (Kanodia, 2007). HPVs exhibit several mechanisms for overcome the apoptotic 
program. E6 binding to p53 stimulates p53 degradation thus preventing p53-dependent 
apoptosis of infected cells. On the other hand, it suppresses FasL E5 mediated apoptosis and 
is associated with reduction to half of the Fas expression.  
Fas (APO-1/CD95) system regulates diverse physiological and pathological mechanisms 
for apoptosis. Interaction between Fas ligand and Fas receptor induces cell death, 
mechanism that could help to destroy HPV-infected keratinocytes. Facilitated cellular 
proliferation (Das et al., 2000), through reduced Fas mediated apoptosis has been 
described in cervical carcinogenesis by immunohistochemistry (Reesink-Peters et al., 
2005) and polymerase chain reaction (Das et al., 2000). On the other hand, the paracrine 
overproduction of Fas-L could facilitate tumour progression by inducing apoptosis of the 
immune cells usually expressing Fas in their membrane, such as CD8 and natural-killer 
cells. During HPV induced cervical carcinogenesis two Fas-related mechanisms may be 
taken into consideration: (a) suppression of apoptosis in infected keratinocytes by 
downregulation of Fas-R expression; and (b) active immunosuppression by Fas-L 
overproduction by tumor cells (Das et al., 2000; Griffith et al., 1995). Granular cytoplasmic 
and membranous Fas-R stains are identified by immunohistochemistry in the normal 
cervix, and their loss has been reported in approximately 50% of squamous intraepithelial 
lesion (SIL) and SCC (Jones & Munger, 1996; Lerma et al., 2008). Fas-R expression by 
tumor cells seems to be unrelated to the stage or quantity of the lymphoid infiltrate and it 
is a constitutive event independent of tumor progression (Lerma et al., 2008). Fas-L 
immunostaining in tumor cells is directly correlated with the tumor stages: 36.4% in stage 
I, 50% in stage II, and 75% in stage III, and inversely correlated with the presence of a 
florid lymphoid infiltrate. This suggest that Fas-L production by tumor cells results in 
decreased lymphoid cell reaction and might be a defence mechanism of the tumor against 
host’s immunity (Lerma et al., 2008). 
Bcl2 protein is localized in the mitochondrial membrane, the endoplasmic reticulum and in 
the nucleus. Bcl2 is an oncoprotein blocking cell apoptosis that can be induced by the 
absence of growth factors, alterations in DNA, viral infection, lymphokines action, cytostatic 
drug or radiation therapy. Its overexpression permits the malignant transformation of the 
cells and extends the survival potential of malignant cells. 
The prognostic value in predicting lesion progression is disputed. Guimarães et al., (2005) 
found by immunohistochemical techniques that expression of Bcl2 in HPV-infected cervical 
biopsies is not useful for predicting the progression of HPV-related SIL. On the other hand, 
Singh et al., (2009) noted cytoplasmic expression of Bcl2 protein in cervical dysplasia, a 
various intensity of immunoreactivity between different cytological grades of cervical 
smears and an association with the presence of HPV16/HPV18.  
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Follow-up data revealed that cases with high-risk HPV and co-induced expression of 
apoptosis-regulatory proteins presented a trend to progressive disease (Sing et al., 2009). 
These data confirm the observations of Fonseca-Moutinho et al., (2004), that Bcl2 is an 
independent factor in defining low risk of progression for CIN 3 and co-expression of 
estrogen receptor, progesterone receptor, and Bcl2 may be a useful tool in identifying the 
CIN 3 lesions with low risk of progression toward cervical cancer. Bcl2 has a more 
important value in cancer, the ratio of Bcl2 to Bax expression determining the survival or the 
death following an apoptotic stimulus. In order to establish a new predictor of the outcome 
of radiotherapy for human cervical carcinoma, Harima et al., (1998) established that the 
increased Bcl2 expression after radiotherapy is correlated with poor survival, while 
increased Bax expression after radiotherapy is correlated with good survival; these findings 
suggest that the levels of Bax and Bcl2 expression after radiotherapy are useful prognostic 
markers in patients with human cervical carcinoma (Harima et al., 1998). Some studies 
confirm that evaluation of Bax and Bcl2 expressions provide independent prognostic 
information for the clinical course of the disease and therefore could be developed as 
prognostic indicators for cervical cancer: Bax expression was associated with good survival 
while Bcl2expression was associated with poor survival, and combination of Bcl2+/Bax+ 
was significantly associated with poorer disease free survival (Wootipoom et al., 2004).  
3.6 Markers of chromosomal stability 
Cells that escape from senescence by gene inactivation continue to divide and suffer 
telomeres loss reaching the second proliferative block, stage 2 of mortality (M2); this is 
characterized by massive cell death caused by critical shortness of telomeres and telomeres 
dysfunction. The telomerase is a RNA-dependent DNA-polymerase that synthesizes 
telomeres DNA and provides molecular bases for unlimited proliferative potential. 
Telomerase activity is absent in most normal somatic cells but present in more than 90% of 
tumor cells and immortalized cells in vitro (Kim et al., 1994). Regarding cervical neoplasia, it 
is not clear whether telomerase is activated during the progression of this disease or 
whether HPV16 infection activates directly telomerase in vivo. Most studies on cervical 
tissue or cervical swabs indicate telomerase activation only after progression to 
intraepithelial lesion (Nowak, 2000). Taken together, in vitro and in vivo studies suggest that 
infection with HPV16 and the concomitant expression of E6 is associated with telomerase 
activation. Cervical lesions containing hrHPV in early stages does not present telomerase 
activity or present it at low levels (Nowak, 2000). Some results show that telomerase activity 
appears only when E6 is expressed at elevated levels. The hTERT expression (telomerase 
catalytic subunit) is in agreement with E6 hrHPV role in telomerase activation, but this 
association lost its significance due to strong association between hTERT and stage of 
intraepithelial lesion. One feasible explanation may be done by the recent experiments 
concerning the E6/ E7 dynamics and telomerase expression along with the progressive 
grades (Peitsaro et al., 2004). The initially high levels of E6 decrease dramatically, while 
hTERT mRNA expression and telomerase activity increase by 10 and respectively 4 fold. 
This means that the telomerase activation by E6 HPV is an early event and selection of 
clones with increased telomerase activity will lead to tumor progression and this intimate 
association with gradual lesions hides hTERT association with E6 hrHPV. Taking into 
account that HPV infections have been associated with cervical cancer, telomerase activity 
may be a central mechanism by which HPV infections can lead to malignant transformation 
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of cervical mucosa. Immunohystochemical studies on biopsy specimens have shown that 
normal epithelium is completely negative for hTERT or presents a profile scoring positive 
cells in parabasal layer. More positive cells were observed in the squamous metaplasia 
epithelium and sometimes in suprabasal metaplasia proliferating cells. Positive 
immunostaining was nuclear and limited to a few cells and stromal immunoreactivity was 
strictly associated to lymphocytes having constitutive hTERT expression. CIN lesions and 
cancer present a different pattern: hTERT-positive nuclei are present in all the layers of 
epithelium, but occasional cytoplasm expression can appear (Branca et al., 2006c). 
Paradoxically, there was a decrease in the nuclear staining intensity of hTERT in squamous 
cell carcinomas (Frost et al., 2000; Yan et al., 2004) with an increase in cytoplasm staining 
(Jarboe et al., 2002). Disturbance of the normal translocation mechanisms of hTERT to the 
nucleus, associated with cervical mucosa malignant transformation may be responsible for 
these differences in the expression pattern. Although it has been demonstrated that the loss 
of hTERT immunostaining may be associated with the deregulation of normal translocation 
mechanisms of hTERT to the nucleus, some authors suggest another mechanism involved in 
a reduced hTERT expression in human cancers: inactivation at the transcription level (Bleotu 
et al, 2010). The heterogeneity of both sensitivity and specificity in telomerase detection seen 
between different studies is due to: sample size (smear/lavage versus cervical biopsy), 
contamination with blood or necrotic cells (including telomerase inhibitors, which can lead 
to false-negative results) (Wang et al., 2004) or haemoglobin (a powerful inhibitor of PCR 
reaction). False positive results in strong inflammatory reactions may occur due to 
inflammatory infiltration. 
More recently, some epigenetic modifications were associated with cervix HPV infection. 
Modifications encompass three types of changes: chromatin modifications, DNA 
methylation and genomic imprinting, each of which is altered in cancer cell.  
Generally, HPV infections are followed by epigenetic changes such as methylation of viral 
genes or host genome. The pattern of HPV genes methylation varies depeding with the viral 
life cycle, the presence of disease and possibly the viral type. The de novo methylation of 
HPV DNA could be a host defence mechanism or a strategy that the virus uses to maintain a 
long-term infection, or both. Aberrant methylation of CpG islands in the promoter regions 
of tumour suppressor genes (TSG) is one of several epigenetic changes which contribute to 
carcinogenesis (Kumar & Verma, 2006). Viral oncogenes can induce tumor suppressor gene 
methylation following activation of DNA methyltransferases. For some genes, the 
prevalence of methylated forms increases with disease severity; for others, methylated 
forms are only detected in women with invasive disease. In a recent paper, aberrant DNA 
methylation was found as an early event in carcinogenesis and as an additional molecular 
marker for the early diagnosis. Among all studied genes, three were found as potential 
biomarkers of cervical cancer risk (hypermethylation of CDH13, DAPK1 and TWIST1 
promoters) (Missaoui et al., 2011).  
Aberrant methylation of the p16 gene occurs early within tumor cell populations. p16 is 
more frequently methylated in advanced tumors (Wong et al., 1999) thus suggesting that its 
reactivation could have therapeutic value. In a study performed on 62 cases of squamous 
cell carcinomas, Cheung et al showed that promoter methylation of PTEN was found in 58% 
of patients with persistent disease while those who died of the disease had a significantly 
higher percentage of PTEN methylation. Thus, PTEN was considered an important 
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significant predictor for both total and disease-free survival after controlling age, pathologic 
grade and clinical stage (Cheung et al., 2004). Another studied gene was E-cadherin which 
methylation frequency in cervical cancer varies between 28 and 80.5% (Widschwendter et 
al., 2004a). It appears that E cadherin methylation have prognostic significance, cases with 
no promoter methylation having a better outcome in univariate and multivariate analyses. 
New studies are focused on identification of the methylation status of several genes present 
in the serum or plasma of patients with cervical cancer with regard to their prognostic 
significance.  
In a study on 93 serum samples using the methyLight technique MYOD1 promoter 
methylation was strongly associated with shorter, disease-free and overall survival 
(Widschwendter et al., 2004b). Data suggesting that methylation of gene promoters in 
patients with cervical cancer is a common phenomenon have been reported. Strong 
correspondence between DAPK, p16, and MGMT genes methylation in serum and in 
primary tumors was noted thus allowing the discovery of a potential biomarker in sera. It 
has been found that parallel testing of HPV and PAX1 methylation in cervical swabs confers 
an improved sensitivity than HPV testing alone (80% vs. 66%) without compromising 
specificity (63% vs. 64%) for HSIL/SCC (Yang et al., 2003; Lai et al., 2008). When PAX1 
methylation marker is tested alone, the specificity for HSIL/SCC is 99%. These data 
encourage further studies to identify a set of methylated genes that would have prognostic 
significance as surrogate markers.  
Although the causal relationship between hrHPV infection and cervical cancer is 
demonstrated, HPV infection alone is not sufficient to induce the malignant transformation. 
Other genetic alterations, such as miRNAs, are required. MicroRNAs (miRNAs) are ~22 nt 
single-stranded, non-coding RNAs that generally negatively regulate their target mRNAs at 
a posttranscriptional level. The different expression of miRNAs in cervical cancer cells or 
tissues as compared with normal controls has been reported, and candidate miRNAs 
functioning as oncogenes (including miR-21, miR-127, miR-146a, miR-199a) and tumor 
suppressors (including miR-34a, miR-143, miR-145, miR-200a, miR-218) in cervical cancer 
carcinogenesis have been suggested (Lee et al., 2011 ). Using TaqMan MicroRNA Arrays, 
McBee and colab (McBee, et al, 2011) found that 18 miRNAs were overexpressed and 2 
underexpressed (miRs-218 and 433). Only five miRNAs (miR-21, miR-135b, miR- 223, and 
miR-301b) may have the potential to be used as markers for progression from dysplasia 
toward invasive cervical disease. Some miRNAs might be down regulated in cervical HPV 
infection through methylation (Botezatu et al., 2011).  
3.7 Markers of immune recognition 
HPV presents some features that allow a specific immune behaviour: bypass the immune 
response, persist in the lower genital tract, induce and promote the progression of cervical 
cancer. These characteristics are related to (i) preferential localization of intraepithelial HPV 
infection, (ii) the absence of viral infection on the impact keratinocytes, (iii) the ability of 
HPV to interfere with innate immunity, and (iv) the expression of late proteins antigens 
responsible for generating antibody response. The virus uses some mechanisms to evade 
immune system: (1) it maintain slow infection levels so that only a low amount of virus is 
exposed to the immune system; (2) it exploits the redundancy of genetic code; (3) it mimics 
host proteins; (4) it modulates the antigen presentation; (5) interfere with IFN; (6) inhibition 
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of cytokines and chemokine profile; (7) distortion of adhesion molecules; (8) modulation of 
adhesion molecules; (9) prevention of apoptosis; (10) inhibition of APC migration.  
Several studies have analyzed immunohistochemically different sub-types of immune cells 
in tumor tissue biopsies (TCD4, TCD8, TCD3, BCD20, CD45, CD57, CD68, etc.). The immune 
response to cervical neoplasia varies with the extension of the disease. In SIL, typically 
associated with persistent HPV infection and high viral load, the lymphocyte 
subpopulations percentages estimated by image analysis were 41% for CD4, 45% for CD8, 
7% for CD20, and 7% for CD56 (Kobayashi et al. 2004). Most researchers revealed the 
essential role intra-and peri-tumor cells play in the favourable development of cervical 
cancer, suggesting that certain survival predictors in cervical cancer relapse may be 
involved (Nedergaard et al., 2007, 2008). Such predictors are: inflammatory infiltrate (role in 
promoting long-term survival), low CD3 (role in predicting relapse), high CD8 cell density 
(involved in cervical cancer favourable prognosis) and low CD4 cell (involved in advanced 
stages of disease) (Nedergaard et al., 2007, 2008; Bell et al., 1995; Bethwaite et al., 1996; Chao 
et al., 1999).  
Cytokine profile distortion leads to inappropriate immune response, which may have 
immunosuppressive effects (failure to eliminate infection in host). HPV infections are focal 
and detection of systemic cytokine serum levels are not associated with the clearance or 
persistence of HPV infection (Hong et al., 2010). 
Evaluation of cytokines may predict high-risk HPV clearance or persistence in untreated 
patients with mild dysplasia or less. Among HPV-infected women, IFN-gamma is 
significantly associated with E6, E7 HPV16 and high-risk HPV viral load in the uterine 
cervix. Thus, increased intralesional IFN-gamma may be considered a prognostic marker for 
oncogenic potential of high-risk HPV (Song et al., 2007). The multivariate logistic regression 
analysis showed that IFN-gamma-positive results were significantly associated with 
clearance of high-risk HPV after 12 months of follow-up, suggesting that intralesional IFN-
gamma may be a prognostic marker for clearance of high-risk HPV (Song et al., 2008).  
Most studies regarding cytokine profiles in HPV associated cancers indicate that Th2 
cytokines correlate with progression toward invasive tumors (Bais et al., 2005). So, cervical 
tumors infiltrating lymphocytes have predominantly Th2/Tc2 polarity and regional lymph 
nodes seem to have a high proportion of T cells. However, this is due to the tumor rather 
than to the mechanisms of circumvention used by HPV. Comparing the cytokine profiles in 
cervical secretions of normal cervicitis, presenting or not HPV DNA, it were described high 
levels of IL-10 in HPV + samples (Azar et al., 2004). The early increase of IL-10 in cervical 
lesions can induce the inhibition of immune response against HPV infection. These data 
suggest that the cytokine profile distortion to an immunosuppressive profile can be induced 
by HPV and can cause the development of cancerous lesions (Kanodia et al., 2007). Several 
cytokines have been shown to reduce HPV transcription; this repression involves TGF-ǃ, 
interleukin 1 and TNF-ǂ (H. zur Hausen, 2002). TNF-ǂ repression is lost during malignant 
conversion.  
4. Conclusions 
HPV associated cancer still remains a cause of death in women. Epidemiological studies and 
laboratory data confirmed that persistent infections with high risk human papillomaviruses 
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(hrHPV) cause virtually all cases of invasive cervical cancer. Cofactors and additional 
molecular events are essential for the transformation of cervical epithelial cells. These events 
imply cell changes that can be quantified in order to evaluate the correct status of the 
disease. An ideal marker should be easy to assay in a not invasively collected sample and 
should have a good sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV). To investigate the cancer risks associated with HPV infection, 
sensible tools to asses the risk hierarchysation are requested to be developed, since the 
cytological assessment alone is not sufficient to classify cervical dysplasia. Sometimes, in 
order to discriminate between productive and transforming infection, a combination of 
biomarkers is required. Such combination will allow a correct risks hierarchysation. 
Although there are many studies focused on new potential biomarker for cervical cancer, 
until now few are validated by the scientific community and health care units.  
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